Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

Oral anticoagulants for Asian patients with atrial fibrillation.

Sabir I, Khavandi K, Brownrigg J, Camm AJ.

Nat Rev Cardiol. 2014 May;11(5):290-303. doi: 10.1038/nrcardio.2014.22. Epub 2014 Mar 11. Review. Erratum in: Nat Rev Cardiol. 2014 Dec;11(12):686.

PMID:
24614113
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal.

Lip GY, Wang KL, Chiang CE.

Int J Cardiol. 2015 Feb 1;180:246-54. doi: 10.1016/j.ijcard.2014.11.182. Epub 2014 Nov 26. Review.

PMID:
25463377
4.

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.

Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE.

J Thromb Haemost. 2014 Jun;12(6):824-30. doi: 10.1111/jth.12546.

5.

Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Chan YH, Kuo CT, Yeh YH, Chang SH, Wu LS, Lee HF, Tu HT, See LC.

J Am Coll Cardiol. 2016 Sep 27;68(13):1389-1401. doi: 10.1016/j.jacc.2016.06.062.

6.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

7.

Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Dzeshka MS, Lip GY.

Expert Opin Pharmacother. 2015;16(17):2661-78. doi: 10.1517/14656566.2015.1104301. Epub 2015 Nov 11. Review.

PMID:
26559069
8.

Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).

Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Hylek E, Kowey PR, Mahaffey KW, O'Brien EC, Singer DE, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.

Am Heart J. 2017 Jul;189:40-47. doi: 10.1016/j.ahj.2017.03.024. Epub 2017 Apr 4.

9.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
10.

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation.

Cha MJ, Choi EK, Han KD, Lee SR, Lim WH, Oh S, Lip GYH.

Stroke. 2017 Nov;48(11):3040-3048. doi: 10.1161/STROKEAHA.117.018773. Epub 2017 Oct 3.

PMID:
28974629
11.
12.

Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.

Haft JI.

Clin Appl Thromb Hemost. 2013 Jun;19(3):241-8. doi: 10.1177/1076029612458148. Epub 2012 Sep 4. Review.

PMID:
22952215
13.

Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.

Alcocer L.

Am J Cardiovasc Drugs. 2016 Jun;16(3):171-82. doi: 10.1007/s40256-016-0163-6. Review.

14.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

15.

Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).

Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC; ROCKET AF Investigators.

Circulation. 2014 May 6;129(18):1850-9. doi: 10.1161/CIRCULATIONAHA.113.005754. Epub 2014 Feb 19.

16.

Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.

Chen CH, Chen MC, Gibbs H, Kwon SU, Lo S, On YK, Rosman A, Suwanwela NC, Tan RS, Tirador LS, Zirlik A.

Int J Cardiol. 2015 Jul 15;191:244-53. doi: 10.1016/j.ijcard.2015.03.369. Epub 2015 Mar 27. Review.

PMID:
25978611
17.

Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.

Kozlowski D, Budrejko S, Raczak G, Rysz J, Banach M.

Curr Pharm Des. 2013;19(21):3816-26. Review.

PMID:
23286429
18.

Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.

van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, Schutgens RE, Klijn CJ; APACHE-AF Investigators.

Trials. 2015 Sep 4;16:393. doi: 10.1186/s13063-015-0898-4.

20.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916

Supplemental Content

Support Center